Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib with Cytarabine and Fludarabine in R/R AML and High-Risk MDS
NCT02649764Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2016
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prexasertib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started May 2016; status: completed.
02
Drugs
prexasertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02649764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649764.